🔎 Trials Near Me

Pradžia › Vilkligė › Oklahoma

Vilkligė klinikiniai tyrimai Oklahoma

8 tyrimai dėl Vilkligė ieško dalyvių vietose Oklahoma.

Miestai Oklahoma

Oficialus tyrimo tekstas (anglų kalba)

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  • Sl0044 50262, Oklahoma City
Renkami dalyviai3 fazė
Amžius 16 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06617325

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  • Oklahoma Medical Research Foundation, Oklahoma City
Renkami dalyviai2 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-10-01 · NCT07409181

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  • Research Site, Oklahoma City
  • Research Site, Oklahoma City
Renkami dalyviai3 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07430306

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  • Oklahoma Medical Research Foundation, Oklahoma City
Renkami dalyviaiStebimasis tyrimas
Amžius 16 ir vyresni · Visoms lytims · Atnaujinta 2026-09-03 · NCT07175285

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

  • Oklahoma Medical Research Foundation, Oklahoma City
Renkami dalyviai3 fazė
Amžius 55 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT05799378

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

  • University of Oklahoma, Oklahoma City
Renkami dalyviai1 fazė
Amžius nuo 12 iki 70 · Visoms lytims · Atnaujinta 2026-05-22 · NCT06308978

Safety of the Herpes Zoster Subunit Vaccine in Lupus

  • Oklahoma Medical Research Foundation, Oklahoma City
Renkami dalyviai4 fazė
Amžius nuo 18 iki 90 · Visoms lytims · Atnaujinta 2025-12-26 · NCT05559671

Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.